Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02564029 · ClinicalTrials.gov registry record · Phase 2
PF-06372865 in Subjects With Photosensitive Epilepsy
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT02564029: Completed Phase 2 study, sponsored by Pfizer.
NCT02564029 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02564029, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
PF-06372865 in subjects with photosensitive epilepsy
Primary Outcome
The SPR was defined as the number of frequency steps between and including the lower and upper bound at which a generalized electroencephalogram (EEG) epileptiform activity had occurred, whereby subjects were exposed to 14 different frequencies ranging from 2 to 60 flashes per second. The SPR is then an integer score that ranges from 0 to 14 with lower scores representing better outcomes. The primary outcome measure was based on the average Least Squares Mean (LSmean) effect over the first 6 hou
Interventions
- DRUG Placebo
- DRUG Lorazepam
- DRUG PF-06372865
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-12-16 |
| Est. Completion | 2017-02-07 |
| Phase | Phase 2 |
What the finished NCT02564029 record still lists
NCT02564029 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02564029 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02564029 about?
NCT02564029 is a clinical study titled "PF-06372865 in Subjects With Photosensitive Epilepsy". PF-06372865 in subjects with photosensitive epilepsy
What is the current status of trial NCT02564029?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2015-12-16. Estimated completion is 2017-02-07.
What interventions are being tested in trial NCT02564029?
The interventions under investigation include: Placebo (DRUG), Lorazepam (DRUG), PF-06372865 (DRUG).
Who is sponsoring clinical trial NCT02564029?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02564029's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI